Related Experiment Videos
Apolipoprotein B and apolipoprotein AI as predictors of coronary artery disease
1Division of Cardiology, Royal Victoria Hospital, Montreal, Quebec.
Insights
Plasma levels of apolipoprotein B (ApoB) and apolipoprotein AI (ApoAI) are key indicators for premature coronary artery disease (CAD) risk. Research explores their predictive power compared to cholesterol, focusing on ApoB
Area of Science:
- Cardiovascular Medicine
- Lipid Metabolism
- Biochemistry
Background:
- Premature coronary artery disease (CAD) poses a significant health burden.
- Plasma levels of apolipoprotein B (ApoB) and apolipoprotein AI (ApoAI) are implicated as critical risk factors.
- Understanding the metabolic framework of these lipoproteins is crucial for risk assessment.
Purpose of the Study:
- To review evidence linking ApoB and ApoAI plasma levels to premature CAD risk.
- To present a metabolic framework explaining these associations.
- To compare the predictive value of ApoB and ApoAI against traditional lipid markers like total cholesterol.
Main Methods:
- Review of existing epidemiological and clinical evidence on ApoB and ApoAI in CAD.
- Metabolic analysis to establish a framework for lipoprotein-CAD relationships.
- Comparative analysis of ApoB and ApoAI versus total cholesterol and lipoprotein lipids as CAD predictors.
Main Results:
- ApoB and ApoAI are identified as significant determinants of premature CAD risk.
- ApoB, in particular, shows strong predictive capability, supported by elucidated structural basis.
- Measurement of apoproteins provides deeper insights into lipoprotein metabolism compared to traditional lipid measures.
Conclusions:
- ApoB and ApoAI are superior predictors of premature CAD risk compared to conventional lipid profiles.
- The metabolic framework supports the role of ApoB and ApoAI in cardiovascular risk.
- Development of accurate, commercially available apoprotein assays is essential for clinical application.
Abstract:
The evidence that plasma levels of apolipoprotein B and apolipoprotein AI are important determinants of the risk of premature coronary artery disease (CAD) are reviewed and a metabolic framework for these relations presented. ApoB and apoAI are compared to total cholesterol and to lipoprotein lipids as predictors of CAD. The emphasis is on apoB as this is the particular interest of this laboratory and because a structural basis has been elucidated that may relate the epidemiologic observations about apoB to the metabolic characteristics of low density lipoprotein. The measurement of apoproteins has revealed much that was previously obscure about normal and abnormal lipoprotein metabolism. However, one of the major challenges is the development of an accurate, widely available commercial assay system for apoproteins.